Thursday, 12 June 2014
Research findings of - CARATOL - E CAPSULES
Studies and evaluation done on Caratol - E Capsules
Treatment of Vitiligo is a major problem as its genesis is multifaceted. Recovery of pigments (melanocytes proliferation and melanin induction) and ultimately immunomodulation are essential for the complete cure of Vitiligo.
Topical application of TOLENORM (Extracts of Psoralia corylifolia, Wrightia tinctoria and indigofera tinctoria) has been found to be an effective preparation in the treatment of Vitiligo and well accepted amongst practicing Dermatologists. TOLENORM is a proprietary formulation from Dr. JRK's Siddha Research and Pharmaceuticals Pvt Ltd.Caratol - E has been recommended for concurrent therapy with Topical Tolenorm.
Now, the results of a study conducted and published has conclusively proved that the combination therapy of Tolenorm and Caratol- E improves melanocytes proliferation and has an immunomodulatory performance both being essential factors for repigmentation amongst Vitiligo patients.
Extract of study done are presented below:
The study revealed that nearly 90% of the patients commenced re-pigmentation within 12 weeks in treatment with Tolenorm alone. In combination with Caratol - E, the commencement of re-pigmentation process was faster (10 weeks) and with a higher % of re-pigmentation (25% compared to 15%). Overall, at the end of 50 weeks, the % regimentations in combination treatment were 82.5% as against 55% with Tolenorm alone.
The results of treatment with Tolenorm alone are by themselves very good. It only gets better and faster in combination with Caratol - E.
Ref: Dr. J.R. Krishnamoorthy, Dr. S. Ranganathan, "Clinical and experimental study on certain herbal, mineral and metal compounds used in Siddha Medicine for management of Vitiligo" Journal of Research in Ayurveda and Siddha, PP 1-11, Vol. XXII No 1-2 Jan-June 2001, Published by Central Council for Research in Ayurveda and Siddha, Ministry of Health and Family Welfare, Govt. of In
For more details, please visit us,